Great News to Investors and Patients, But What is Vivus's Ultimate Destiny

The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?

360 Biotech's contrarian thesis on the weight loss drugs developer published in 2013 was unwelcoming but turned out valid. Stock promoters who were overly exuberant on Arena, Orexigen, and/or VIVUS mislead investors.

The Story. VIVUS FDA approved obesity drug, Qsymia, has better efficacy in terms of more weight reduction than Belviq, Contrave, and Orlistat.

The FDA issued a delay for Orexigen's (OREX) obesity drug Contrave, The stock has now fallen by more than 15% in pre-market trading, creating an investment opportunity for patient investors.

Stock market averages are up sharply and led by the financials Friday.